Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Gelfond

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The Journal of Clinical Endocrinology and Metabolism|December 10, 2024
Glycemia and Insulin Secretion in Cystic Fibrosis Two Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDOChristine L Chan, Meghan Shirley Bezerra, Darko Stefanovski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 23, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapyDave P Nichols, Scott H Donaldson, Carla A Frederick, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialDavid P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The Journal of Clinical Endocrinology and Metabolism|December 10, 2024
Glycemia and Insulin Secretion in Cystic Fibrosis Two Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDOChristine L Chan, Meghan Shirley Bezerra, Darko Stefanovski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 23, 2021
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapyDave P Nichols, Scott H Donaldson, Carla A Frederick, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialDavid P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
Pageof 4